This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2000 Oct 18;284(15):1971-3.

doi: 10.1001/jama.284.15.1971.

Dopamine agonists in early therapy for Parkinson disease: promise and problems

PMID: 11035895
DOI: 10.1001/jama.284.15.1971

Editorial

Dopamine agonists in early therapy for Parkinson disease: promise and problems

C M Tanner. JAMA. 2000.

. 2000 Oct 18;284(15):1971-3.

doi: 10.1001/jama.284.15.1971.

Author

PMID: 11035895
DOI: 10.1001/jama.284.15.1971

No abstract available

PubMed Disclaimer

Comment on

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group. Parkinson Study Group. JAMA. 2000 Oct 18;284(15):1931-8. doi: 10.1001/jama.284.15.1931. JAMA. 2000. PMID: 11035889 Clinical Trial.

Similar articles

Current advances in Parkinson's disease.
Ball J. Ball J. Trends Neurosci. 2001 Jul;24(7):367-9. doi: 10.1016/s0166-2236(00)01850-6. Trends Neurosci. 2001. PMID: 11467283 No abstract available.
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
MacMahon DG. MacMahon DG. Age Ageing. 2003 May;32(3):244-5. doi: 10.1093/ageing/32.3.244. Age Ageing. 2003. PMID: 12720606 No abstract available.
Pramipexole, ropinirole, and mania in Parkinson's disease.
Singh A, Althoff R, Martineau RJ, Jacobson J. Singh A, et al. Am J Psychiatry. 2005 Apr;162(4):814-5. doi: 10.1176/appi.ajp.162.4.814-a. Am J Psychiatry. 2005. PMID: 15800169 No abstract available.
Ropinirole and pramipexole, the new agonists.
Hobson DE, Pourcher E, Martin WR. Hobson DE, et al. Can J Neurol Sci. 1999 Aug;26 Suppl 2:S27-33. doi: 10.1017/s0317167100000068. Can J Neurol Sci. 1999. PMID: 10451757 Review.
New drugs for the treatment of Parkinson's disease.
LeWitt PA. LeWitt PA. Pharmacotherapy. 2000 Jan;20(1 Pt 2):26S-32S. doi: 10.1592/phco.20.2.26s.34631. Pharmacotherapy. 2000. PMID: 10641989 Review.

See all similar articles

Cited by

Rasagiline in treatment of Parkinson's disease.
Nayak L, Henchcliffe C. Nayak L, et al. Neuropsychiatr Dis Treat. 2008 Feb;4(1):23-32. Neuropsychiatr Dis Treat. 2008. PMID: 18728823 Free PMC article.
Benefit-risk considerations in the treatment of dementia with Lewy bodies.
Swanberg MM, Cummings JL. Swanberg MM, et al. Drug Saf. 2002;25(7):511-23. doi: 10.2165/00002018-200225070-00005. Drug Saf. 2002. PMID: 12093309 Review.
Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management.
Shen Y, Huang JY, Li J, Liu CF. Shen Y, et al. Chin Med J (Engl). 2018 Apr 20;131(8):974-981. doi: 10.4103/0366-6999.229889. Chin Med J (Engl). 2018. PMID: 29664059 Free PMC article. Review.
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group. Bracco F, et al. CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003. CNS Drugs. 2004. PMID: 15330687 Clinical Trial.
Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.
Factor SA. Factor SA. Curr Treat Options Neurol. 2001 Nov;3(6):479-493. doi: 10.1007/s11940-001-0011-z. Curr Treat Options Neurol. 2001. PMID: 11581525

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information